The Science Behind Magic Mushrooms

Psilocybin research has accelerated dramatically since the early 2000s, when institutions like Johns Hopkins University, Imperial College London, and NYU Langone launched the first rigorous modern clinical trials. As of 2026, over 100 peer-reviewed studies have been published, the FDA has granted Breakthrough Therapy designation for both treatment-resistant depression and major depressive disorder, and Phase III trials are underway that may lead to regulatory approval.

The research spans multiple therapeutic applications — from depression (the most advanced, with 12-month remission data) to PTSD, addiction, end-of-life anxiety, OCD, and eating disorders. Brain imaging studies have revealed how psilocybin disrupts the default mode network (DMN) and promotes neuroplasticity — providing a mechanistic basis for its clinical effects.

Key milestones: the 2016 Johns Hopkins/NYU cancer anxiety studies (published simultaneously, with a New England Journal of Medicine editorial calling them "remarkable"), the 2021 Imperial College head-to-head comparison with the SSRI escitalopram, the 2023 Johns Hopkins 12-month follow-up showing 58% depression remission, and Compass Pathways' ongoing Phase III COMP360 trial — the largest psilocybin RCT to date.

Browse the categories below to explore the evidence by research type, or visit our condition-specific guides for how the science applies to particular diagnoses.